Details of the Drug Reposition

General Information of This Drug (ID: DMCNTFW)

Drug Name
Ad-RTS-hIL-12   DMCNTFW
Drug Type
Gene therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Glioblastoma of brain DISESTHB 2A00.00 Phase 2 [1]
Melanoma DIS1RRCY 2C30 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04006119) Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma. U.S. National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033476)